IVAX VERAPAMIL ER SALES ARE $145.9 MIL. IN 1993, OR 29% OF PHARMACEUTICAL NET REVENUES OF $500.5 MIL.; VALUE HEALTH 12-MONTH Rx DRUG REVENUES ARE $364.7 MIL.
Ivax sales of verapamil extended-release tablets totaled $145.9 mil. in 1993 and were $50.8 mil. in the fourth quarter, the healthcare and consumer products holding company reported Feb. 28.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth